Hofseth Biocare inks research deal with Stanford University

Norwegian biotechnology firm Hofseth BioCare inked a two-year research deal with Stanford University School of Medicine in the United States to investigate the health effects of the company's salmon hydrolysate peptides (SPH) on children and adults struggling from gastrointestinal issues.

The study's focus will be on whether SPH can reduce or prevent inflammation of the intestine.

Hofseth BioCare closed out 2019 in the red again, as its operating loss reached NOK 79 million (€6.7 million/$7.2 million), a 3 percent increase over the previous year.